Marksans Pharma Ltd Expansion of Product Portfolio in Regulated Markets (UK & US)

Executive Summary Marksans Pharma continues to demonstrate strong regulatory momentum, securing multiple product approvals in key regulated markets this week. The latest approval from the UK health regulator reinforces the company's foothold in the European region, which remains a significant revenue driver. Key Developments New UK MHRA Approval: The company’s UK subsidiary, Relonchem Limited, has received Marketing Authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Cetirizine Dihydrochloride 1 mg/ml oral solution. This addition strengthens their anti-allergy portfolio, addressing high-demand indications such as hay fever and hives. Regulatory Streak: This marks the third major regulatory win for Marksans this week, highlighting robust R&D and compliance capabilities: UK: Approval for Mefenamic Acid film-coated tablets (250 mg & 500 mg). USA: Final approval from the US FDA for Loperamide Hydrochloride Tablets USP, 2 mg (OTC anti-diarrhoeal). Financial Context & Outlook (Q2 FY26) The expansion of the product basket is critical for Marksans to sustain growth amidst a challenging pricing environment. Revenue Performance: The company reported a 12% YoY revenue growth (₹720 crore) in Q2 FY26. The UK & Europe business remains a pillar of strength, contributing ₹245.3 crore during the quarter. Margin Pressure: EBITDA margins compressed to 20% (down from 23%) due to pricing pressures. The launch of new molecules—like Cetirizine and Mefenamic Acid—is strategically vital to drive volume growth and offset pricing erosion. Profitability: Net Profit remained stable with a modest 1.5% YoY increase to ₹98.2 crore. Market Reaction The street reacted positively to the pipeline expansion, with the stock closing at ₹193.02, up 2.05% in the previous trading session.